A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound.

ABSTRACT: Hepatitis C virus (HCV) is a global pathogen and infects more than 185 million individuals worldwide. Although recent development of direct acting antivirals (DAA) has shown promise in HCV therapy, there is an urgent need for the development of more affordable treatment options. We initiated this study to identify novel inhibitors of HCV through screening of compounds from the National Cancer Institute (NCI) diversity dataset. Using cell-based assays, we identified NSC-320218 as a potent inhibitor against HCV with an EC₅₀ of 2.5 μM and CC₅₀ of 75 μM. The compound inhibited RNA dependent RNA polymerase (RdRp) activity of all six major HCV genotypes indicating a pan-genotypic effect. Limited structure-function analysis suggested that the entire molecule is necessary for

SUBMITTER: Madhvi A 

PROVIDER: S-EPMC5517564 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature